miRNAs (microRNAs) are frequently and aberrantly expressed in many cancers. MiR-873 has been revealed to be downregulated in colorectal cancer and glioblastoma. However, its function remains unclear. Here we report that miR-873 is downregulated in breast tumor compared with normal tissue. Enforced expression of miR-873 decreases the transcriptional activity of ER (estrogen receptor)-α but not ERβ through the modulation of ERα phosphorylation in ER-positive breast cancer cells. We also found that miR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of miR-873. CDK3 was shown to be overexpressed in breast cancer and phosphorylate ERα at Ser104/116 and Ser118. Furthermore, we found that Mir-873 inhibits ER activity and cell growth via targeting CDK3. Interestingly, miR-873 was observed to be downregulated in tamoxifen-resistant MCF-7/TamR cells, while CDK3 is overexpressed in these cells. More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells. Our data demonstrate that miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer.
INTRODUCTION
Breast cancer is the most common type of cancer and one of the leading causes of cancer-related death in women worldwide. The estrogen receptor (ER), which has a prominent role in breast cancer, is a member of the nuclear receptor superfamily of ligandactivated transcription factors. 1, 2 There are two different forms of the ER, α and β, each encoded by a separate gene (ESR1 and ESR2, respectively). 3 On binding estrogen, the ER undergoes conformational changes and binds to the estrogen response elements (ERE), which are located on the upstream sequences of estrogen-responsible genes such as TFF1 and c-Myc. 4, 5 The ER protein is a composite of multiple domains including a DNAbinding domain and two major transcriptional activation function (AF) domains, AF-1 and AF2. The AF1 domain located in the N terminus is a ligand-independent transactivation domain. Its function can be enhanced by phosphorylation through the mitogen-activated protein kinase and AKT pathways. The AF-2 domain located in the C terminus has a ligand-dependent function. [6] [7] [8] Similar to other nuclear receptors, ER regulates target genes by recruiting transcriptional co-regulators and components of the basal transcription machinery. The ligand-bound ER, depending on the nature of the ligand, recruits and interacts with co-regulatory proteins that can either enhance (co-activators) or repress (co-repressors) it's transcriptional activity. [9] [10] [11] [12] Approximately 70% of breast cancers are ER positive and the majority fully depends on estrogen signaling. Thus, disruption of ER function is the main therapeutic strategy employed in targeting the disease. 2, 13 The selective ER modulator, tamoxifen, can bind to the ER and block the interaction between estrogen and the ER. Tamoxifen has been the mainstay of endocrine therapy in both early and advanced breast cancer patients for almost three decades. [14] [15] [16] Unfortunately, it is known that not all patients with ER-positive breast cancer respond to tamoxifen (known as de novo resistance). Moreover, many patients that receive tamoxifen as adjuvant therapy eventually acquire tamoxifen resistance (acquired resistance). Thus, tamoxifen resistance, either de novo or acquired, presents a major challenge in treating breast cancer. [17] [18] [19] [20] [21] MicroRNAs (miRNAs) are 20-to 22-nucleotide-long noncoding RNAs. They mostly anneal in the 3′-untranslated region (UTR) of protein-coding mRNAs leading to posttranscriptional silencing of their respective genes. It is becoming increasingly evident that miRNAs are key modulators of breast cancer initiation and progression. miRNAs can function as oncogenes or tumor suppressor genes depending on their gene targets. 22, 23 A recent METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study has provided a system-level analysis of miRNA expression profiles across a large number of human breast tumors and revealed oncogenic and tumor-suppressive roles of differential miRNAs. 24 More than 10 miRNAs were found to target ERα and its co-regulators that regulate ERα transcriptional activities. 25 Several recent studies have revealed the roles of miRNAs in tamoxifen resistance. Specifically, miR-221/222 was able to confer resistance to tamoxifen, potentially owing to their large genetargeting spectrum. 26 Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in tamoxifen-resistant cells. Re-expression of miR-375 was sufficient to sensitize resistant cells to tamoxifen and partly reversed epithelial to mesenchymal transition via directly targeting the oncogene, metadherin. 27 We screened several poorly understood miRNAs, which have been reported to be downregulated in cancer, and found that miR-873 is downregulated in breast tumor compared with normal tissue. MiR-873 has been shown to be downregulated in colorectal cancer and glioblastoma; however, its function has not been reported. 28, 29 Here we found that miR-873 could inhibit ERα phosphorylation and its transcriptional activity via targeting cyclin-dependent kinase 3 (CDK3). MiR-873 was shown to have an important role in breast cancer cell proliferation and tumor growth. We also revealed that mir-873 regulates tamoxifen resistance in breast cancer cells.
RESULTS

MiR-873 regulates ER signaling in breast cancer cells
According to the databases of recent studies, several miRNAs with unknown functions have shown reduced expression in many types of human cancer. 24, 28, 30 In order to screen novel miRNAs, which are downregulated in breast cancer, we performed realtime PCR to investigate the expression of selected miRNAs. As a result, four miRNAs were found to be downregulated in breast cancer compared with normal tissue. Among four miRNAs identified, miR-873 expression was reduced by more than ninefold compared with normal tissue ( Supplementary Table S1 ).
Estrogen signaling and the ER have a pivotal role in breast cancer initiation and progression, and the majority of human breast cancers start out as estrogen dependent. 1, 2 To investigate the role of miR-873 in ER signaling, the expression plasmid for miR-873 or control vectors were co-transfected with ERE-Luc into breast cancer cells. We used real-time PCR to validate that the transfection of miR-873 significantly elevated miR-873 levels in both MCF-7 and SKBR3 cells ( Figure 1a ). As shown in Figure 1b , overexpression of miR-873 inhibited luciferase reporter activities in both the absence and presence of estrogen in MCF-7 cells. Interestingly, miR-873 significantly decreased reporter activity in response to the ERα-specific agonist propylpyrazole triol but not to the ERβ-specific agonist, diarylpropionitrile. These results indicate that miR-873 inhibits ERα but not ERβ transcriptional activity. To verify the specific effect of miR-873 on ERα, we cotransfected ERα or ERβ plasmids with miR-873 in ERα-and ERβnegative SKBR3 breast cancer cells. Consistent with the results in MCF-7, miR-873 specifically inhibited ERα transcriptional activity only ( Figure 1c ).
To determine whether endogenous miR-873 is involved in ER transactivation, we used anti-miR-873 inhibitor to diminish miR-873 expression in MCF-7 cells. As expected, the anti-miR-873 inhibitor oligo effectively inhibited miR-873 expression, whereas the control oligo had no effect ( Figure 1d ). As shown in Figure 1e , suppression of the normal expression of miR-873 in MCF-7 cells significantly enhanced the ERα transcriptional activity.
Moreover, we also examined the effect of miR-873 on several well-known endogenous ERα target genes. We found that overexpression of miR-873 inhibited TFF1 and c-Myc expression at both the mRNA ( Figure 1f ) and protein ( Figure 1g ) levels. To investigate how miR-873 decreases transactivation of ERα, we examined the effect of miR-873 on ERα expression and its phosphorylation level. In the absence or presence of E2, enforced expression of miR-873 did not alter ERα expression. However, overexpression of miR-873 inhibited phosphorylation of S118 but not S167 ( Figure 1h ). We then performed chromatin immunoprecipitation to investigate the effect of miR-873 on the occupancies of ERα and its co-activators. As a result, enforced expression of miR-873 inhibited the recruitments of ERα and its co-activators (CBP, MED1 and AIB1) to TFF1 and c-Myc promoter (Figure 1i and Supplementary Figure S1 ).
MiR-873 inhibits cell growth in vitro and in vivo Our above data indicated a key role for miR-873 in ERα-mediated transcription. Thus, we further assessed the role of miR-873 in the growth of ER-positive breast cancer cells. We first performed cell proliferation assays on cells, which stably expressed miR-873. Overexpression of miR-873 significantly diminished cell proliferation of MCF-7 and ZR75-1 cells (Figure 2a and Supplementary Figure S2 ), while suppression of miR-873 in MCF-7 cells significantly enhanced cell proliferation ( Figure 2b ). Next, we determined the role of miR-873 in anchorage-independent colony formation using a soft agar assay. We found that overexpression of miR-873 significantly reduced the number and size of the colonies formed ( Figures 2c and d) .
To confirm whether the biological effects of miR-873 observed in cultured cells are relevant to tumor growth in vivo, stable miR-873-overexpressing cells were injected into nude mice. As shown in Figures 2e and f, overexpression of miR-873 reduced tumor size and weight when compared with control groups. The expression of miR-873 in tumors was confirmed by reverse transcription-PCR (data not shown). Taken together, these data indicate that miR-873 has an important role in the growth of breast cancer cells, both in vitro and in vivo. inhibited ERα target gene expression. MCF-7 cells were infected with lentivirus containing miR-873 or control vector, followed by real-time reverse transcription-PCR (f) and western blotting (g) analyses of ERα target gene expression. (h) MiR-873 inhibited ERα S118 phosphorylation. MCF-7 cells were infected with lentivirus containing miR-873 or control vector, followed by western blot analyses of ERα phosphorylation level. (i) MiR-873 inhibited the recruitments of ERα and its co-activators. MCF-7 cells were infected with lentivirus containing miR-873 or control vector, followed by chromatin immunoprecipitation, to detect the recruitments of ERα and its co-activators (*Po0.05, **Po 0.01, miR-873 versus control plasmid under the same treatment).
MiR-873 directly targets CDK3
To understand the mechanisms by which miR-873 inhibits ERα signaling, several computational methods were used to help identify miR-873 targets in humans. As miR-873 reduced ERα phosphorylation, we hypothesized that its potential targets should include kinases. Among those potential targets, CDK3 is of particular interest because its homolog, CDK2, was previously implicated in phosphorylating ERα and enhancing its transcriptional activity. Therefore, we decided to carry out a series of experiments to determine whether CDK3 is a direct target of miR-873. First, we detected the effect of miR-873 on CDK3 expression. Although miR-873 overexpression did not change CDK3 mRNA levels, there was a clear reduction in CDK3 protein levels in MCF-7 and T47D cells (Figures 3a and b ). However, miR-873 silencing caused an increase in CDK3 protein levels in MCF-7 and T-47D cells (Figure 3c ). As a control, miR-873 did not affect CDK2 protein expression. These findings suggest that miR-873 targets CDK3 through translational inhibition. Next, we generated wild-type and mutant CDK3-3′-UTR expression plasmids that were fused to a luciferase reporter according to the matched sequence between CDK3-3′-UTR and miR-873 ( Figure 3d ). We found miR-873 overexpression significantly inhibited luciferase activity of wild-type but not mutant reporter genes in MCF-7 and T47D cells (Figure 3e and Supplementary Figure S3a ). However, miR-873 silencing specifically enhanced the luciferase activity of wild-type but not mutant CDK3-3′-UTR ( Figure 3f and Supplementary Figure S3b ).
In order to study the correlation of miR-873 and CDK3 in breast cancer, we performed real-time PCR and western blotting using 20 patient samples and 5 adjacent noncancerous tissues. A negative correlation between miR-873 and CDK3 was observed in the breast cancer samples ( Figure 4 ).
CDK3 phosphorylates ER and enhances ER activity
It has been shown that CDK2 phosphorylates ERα and enhances its transcriptional activity. 31 As CDK3 has high homology with CDK2, we deduced that CDK3 also interacts and phosphorylates ERα. In order to examine this possible interaction between CDK3 and ERα, N-terminally FLAG-tagged, full-length CDK3 and MYC-tagged ERα were expressed in HEK293T cells and treated with estrogen. FLAG-CDK3 was immunoprecipitated from cell lysates by an anti-FLAG antibody and analyzed for ERα binding by western blot analysis. As shown in Figure 5a , ERα was co-immunoprecipitated and detected in the presence and absence of estrogen. This result demonstrates that CDK3 interacts with ERα in vivo in a ligandindependent manner.
To ascertain the interaction of CDK3 with ERα in a more physiological context, the endogenous CDK3 protein from MCF-7 cells was immunoprecipitated with anti-CDK3 antibody. Subsequent blotting with anti-ERα antibody indicated that the endogenous CDK3 interacted with ERα ( Figure 5b ). Next, we performed reverse co-immunoprecipitation in MCF-7 cells and confirmed the interaction between these two proteins (Supplementary Figure S4 ). Finally, we performed glutathione Stransferase (GST) pull-down assay and the result showed that CDK3 directly interacts with ERα ( Figure 5c ).
To determine whether CDK3 phosphorylates ERα, we performed a kinase assay and detected ERα phosphorylation using phosphorylation site-specific antibodies of ERα. As shown in Figure 5d , GST-ERα but not GST was phosphorylated at three sites: Ser104, 106 and 118. Next, we carried out experiments using MCF-7 cells to ascertain the effect of CDK3 on ERα phosphorylation. As shown in Figure 5e , we found that knockdown of CDK3 significantly decreased ERα phosphorylation at Ser104, 106 and 118 in MCF-7 cells. These results indicate that CDK3 phosphorylates ERα at Ser104, 106 and 118. To determine the biological significance of ERα phosphorylation by CDK3, we examined ERα activity with an ERE-luciferase reporter gene assay in MCF-7 cells. Knockdown of CDK3 by specific short hairpin RNA (shRNA) led to a significant decrease of ER activity (Figure 5f ). CDK3 is overexpressed in breast cancer and positively regulates breast cancer cell proliferation It has been reported that CDK3 is overexpressed in human glioblastoma tissue and enhances cell transformation. 32 To investigate whether CDK3 is overexpressed in human breast cancer, we carried out a tissue microarray using anti-CDK3 antibody. We found that CDK3 exhibited a very low level in normal breast tissues, yet it was overexpressed in breast cancer tissues (Figures 6a and b ). Next, we detected CDK3 expression in breast cancer cells and found that compared with normal breast cell MCF-10A, CDK3 has a higher protein level in breast cancer cells ( Figure 6c ).
To study the effects of CDK3 on cell proliferation, we infected MCF-7 and ZR75-1 cells with lentivirus-expressing control scramble or CDK3 shRNA, and measured cell proliferation by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay after control vehicle or estrogen treatments. As shown by western blot analyses (Figure 6d ), CDK3 shRNA treatment successfully knocked down CDK3 protein expression in both cell lines. Importantly, we found that CDK3 knockdown significantly inhibited MCF-7 and ZR75-1 cell proliferation, as compared with scramble shRNA-treated cells (Figures 6e and f).
MiR-873 inhibits ER activity and cell growth via targeting CDK3
To further explore whether CDK3 is a functional target of miR-873, we re-introduced the CDK3 coding sequence without the 3′-UTR through lentivirus infection into cells stably overexpressing miR-873. Western blots showed that CDK3 lentivirus infection restored CDK3 expression, which was inhibited by miR-873 in MCF-7 cells (Figure 7a ). We then measured ERα transcriptional activity and found that re-expression of CDK3 diminished the inhibitory effect of miR-873 on ERα transcriptional activity ( Figure 7b ). We also found that overexpression of CDK3 restored the recruitments of ERα and its co-activators, which were inhibited by miR-873 (Supplementary Figure S5 ). Real-time PCR assays showed that overexpression of CDK3 could restore ER target genes such as TIFF1 and c-Myc expression, which were inhibited by miR-873 ( Figure 7c ). In addition, we also found that knockdown of CDK3 significantly decreased ER target gene expressions (Supplementary Figure S6 ). We further investigated whether miR-873 inhibits cell proliferation via targeting CDK3. As a result, we found that overexpression of CDK3 diminished the inhibitory effect of miR-873 on cell proliferation. Soft agar assays also suggested that overexpression of CDK3 could restore cell transformation, which was inhibited by miR-873 in MCF-7 cells (Figures 7d and e ).
MiR-873 regulates tamoxifen resistance in breast cancer cells via targeting CDK3
Several studies have demonstrated that direct inhibition of cyclindependent kinases may overcome the problem of resistance to anti-estrogen treatments in breast cancer. 33, 34 We decided to carry out experiments to investigate whether miR-873/CDK3 could regulate tamoxifen resistance in breast cancer cells. To address this possibility, we generated the tamoxifen-resistant cell line MCF-7/TamR. Resistance of the cells to tamoxifen was verified by cell viability assays (Supplementary Figure S7) . We then investigated miR-873 and CDK3 expression in MCF-7/TamR cells. As shown in Figures 8a and b , compared with parental MCF-7 cells, miR-873 was present at lower levels in MCF-7/TamR cells, while CDK3 was present at significantly higher levels in MCF-7/ TamR cells. We next investigated whether miR-873 could be involved in tamoxifen resistance in MCF-7/TamR cells. For this purpose, MCF-7/TamR cells were stably transfected with either control or miR-873 expression vectors, and treated with or without tamoxifen. Enforced expression of miR-873 was capable of sensitizing MCF-7/TamR cells to tamoxifen. Importantly, transfection of CDK3 reversed the effect of miR-873 on tamoxifen resistance in MCF-7/TamR cells (Figure 8c ). In addition, knockdown of CDK3 was also capable of sensitizing MCF-7/TamR cells to tamoxifen (Supplementary Figure S8) .
Previous studies have shown that tamoxifen has an agonist role on ERα-mediated transcription in tamoxifen-resistant cells. 18, 35 To determine the effect of miR-873 on ERα transcriptional activity and estrogen-responsive gene expression in response to tamoxifen, we decided to carry out a series of experiments. In agreement with previous studies, we found that tamoxifen could induce ERα transcriptional activity in MCF-7/TamR cells. We also found that overexpression of miR-873 could inhibit ERα transcriptional activity by tamoxifen treatment in MCF-7/TamR cells. More importantly, transfection of CDK3 could abolish this tamoxifeninduced ERE reporter gene inhibition by miR-873 ( Figure 8d ). Along with this, we also examined the effects of miR-873 on tamoxifen-induced expression of endogenous ERα target genes in MCF-7/TamR cells. As shown in Figure 8e , our results indicate that miR-873 inhibited tamoxifen-induced expression of ERα target genes. We also examined the potential effect of miR-873 on the recruitments of the co-repressors N-CoR and SMRT, as they have been shown to have important roles in the anti-proliferative action of tamoxifen. 10, 11, 36 As expected, tamoxifen failed to recruit N-CoR and SMRT in tamoxifen-resistant cells. However, tamoxifen was shown to recruit N-CoR and SMRT in MCF-7 cells (Supplementary Figure S9 ). Enforced expression of miR-873 effectively restored the recruitments of N-CoR and SMRT by tamoxifen to TFF1 promoter (Figure 8f ).
To determine the role of miR-873 on tamoxifen resistance in vivo, cells stably expressing miR-873 were injected into nude mice and then these mice were treated with tamoxifen. As expected, tamoxifen treatment alone did not significantly alter tumor growth compared with vehicle control group in mice injected with MCF-7/TamR cells. However, tamoxifen treatment could further potentiate tumor growth inhibition by miR-873 Figure 5 . CDK3 interacts and phosphorylates ERα. (a) FLAG-tagged CDK3 and MYC-tagged ERα or empty vectors were co-transfected into HEK293T cells. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody and the precipitates were then immunoblotted with anti-MYC antibody. (b) MCF-7 cells were treated with and without 10 nM E 2 for 1 h. Cell lysates were immunoprecipitated with either anti-CDK3 antibody or control IgG. The precipitates were analyzed by western blotting using anti-ERα. (c) Direct interaction of CDK3 with ERα. Glutathione-Sepharose beads bound with GST-ERα (1-282) or with GST were incubated with the lysates of MCF-7 cells, which were transfected with FLAG-CDK3. After washing the beads, the bound proteins were analyzed by western blotting using anti-FLAG antibody. (d) CDK3 phosphorylates c-Jun at Ser104/106 and 118. An in vitro kinase assay was conducted with active CDK3 and GST-ERα (1-282). Phosphorylation of ERα at Ser104/106 and Ser118 was analyzed using phospho-specific antibodies and western blotting. (e) MCF-7 cells were infected with lentivirus expressing scramble or CDK3 shRNA and then treated with E 2 or vehicle. ERα phosphorylation level was detected using phospho-specific antibodies as indicated. (f) MCF-7 cells were transfected with CDK3 shRNA or scramble shRNA, along with plasmids expressing ERE-TK-LUC reporter and PRL-TK, followed by vehicle or E2. The relative luciferase values are expressed as mean ± s.e. (*Po 0.05, CDK3 shRNA versus scramble under the same treatment).
( Figure 8g ). These results suggest that miR-873 sensitizes breast cancer cells to tamoxifen in vivo.
DISCUSSION
High-throughput sequencing revealed that miR-873 is downregulated in colorectal cancer and glioblastoma, but its role in cancer has not been determined. 28, 29 In this study, we have investigated the role of miR-873 as a negative regulator of both ER-mediated transcription and breast cancer cell growth. Initially, we demonstrated that miR-873 inhibits the transcriptional activity of ERα but not ERβ, thereby modulating estrogen-responsive genes. MiR-873 was also found to inhibit the proliferation of breast cancer cells and tumor growth in vitro. We then noted that miR-873 decreases ERα Ser118 phosphorylation and ERα recruitments on ERE sequences. Our data also showed that miR-873 directly targets CDK3 (CDK3 can phosphorylate ERα and enhance its transcriptional activity). Lastly, we found that miR-873 is further downregulated in tamoxifen-resistant cells and re-expression of miR-873 can restore tamoxifen sensitivity. Taken together, these findings support a key role for miR-873 in breast cancer development and tamoxifen resistance.
Studies have shown that miRNAs may function as oncogenes or tumor suppressors in many cancers, depending on which genes or pathways they regulate. 22, 23 miRNAs have been implicated in almost all aspects of cancer biology, including proliferation, apoptosis, invasion, metastasis, angiogenesis and drug resistance. [37] [38] [39] New technical developments such as small RNA high-throughput sequencing have revealed novel cancer-related miRNAs. Using this kind of sequencing, miRNAs, such as miR-873, having unknown function were found to be significantly downregulated in the glioblastomas. 29 In colorectal cancer, highresolution chromatin immunoprecipitation-seq revealed that miR-873 is epigenetically silenced. 28 A recent METABRIC study has described the miRNA profile in breast cancer. 24 Consistent with the METABRIC study, miR-873 was shown to be downregulated in breast cancer through a reverse transcription-PCR screen in our study. Our study further demonstrated overexpression of MiR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. These findings along with previous studies indicate that miR-873 may function as a common tumor suppressor.
Mechanistically, the downregulation of miR-873 in ER-positive breast cancer may suggest that miR-873 has an important role in ER signaling regulation. 24 Indeed, we found that miR-873 specifically inhibits ERα but not ERβ transcriptional activity and decreases ERα phosphorylation level. Several miRNAs have been implicated in disrupting ER activity through targeting the ER or its co-regulators. 25 To our knowledge, this is the first study to report that an miRNA can regulate the ER phosphorylation level. Indeed, ER phosphorylation has an important role in breast cancer initiation and tamoxifen resistance. Thus, this study provides an alternative mechanism to regulate ER signaling for miRNAs.
Endocrine resistance remains a major challenge in the field of breast cancer. Recent studies have revealed roles of miRNAs in tamoxifen resistance. Downregulation of miR-375 and miR-451 are associated with tamoxifen resistance in breast cancer and reexpression of miR-375 reverses tamoxifen resistance. 27, 40 However, miR221/222 is upregulated in both tamoxifen-resistant cells and patients, and confers resistance to tamoxifen via targeting p27. 26 In this study, we revealed a role of miR-873 in tamoxifen resistance. MiR-873 was found to be downregulated in tamoxifenresistant cells and re-expression of miR-873 restored the sensitivity of cells to tamoxifen. Our data also indicated that miR-873 functions in tamoxifen resistance via targeting CDK3. As miR-221-/222 targets p27, an inhibitor of CDK3, it is very interesting to study their expression relationship and whether they cooperate in tamoxifen resistance in breast cancer. In addition, we have investigated the effect of miR-873 on CDK3 expression in MDA-MB-231 and SKBR3 cells. Overexpression of miR-873 reduced CDK3 expression by 1.9-and 2.4-fold, respectively (data not shown). This suggests that targeting of CDK3 by miR-873 is not specific in ER-positive breast cells but miR-873 exhibits a much stronger effect on regulating CDK3 expression in ER-positive compared with ER-negative breast cancer cells.
There are two possible mechanisms for miR-873 to be involved in tamoxifen resistance. MiR-873 may inhibit ER phosphorylation at Ser104/106 and 118 via targeting CDK3, which would restore the sensitivity of resistant cells to tamoxifen. These phosphorylation sites on the ER have been implicated to have an important role in tamoxifen resistance. 41, 42 A second mechanism for miR-873 could be due to the restoration of tamoxifen-induced recruitments of N-CoR and SMRT on ERE. Transcriptional co-repressors N-CoR and SMRT have been shown to have important roles in the antiproliferative action of tamoxifen in breast cancer cells. 10, 11, 36 In the presence of tamoxifen, ERα is known to preferentially bind and recruit the transcriptional co-repressors N-CoR and SMRT to target gene promoters. The anti-proliferative effect of tamoxifen depends on the recruitment of these co-repressors. However, ERα fails to recruit N-CoR and SMRT in tamoxifen-resistant cells. 18 Thus, recruitment restoration of N-CoR and SMRT is very important to overcome tamoxifen resistance. Interestingly, there is a possible linkage between ERα phosphorylation and co-repressor recruitments. It has been reported that in a tamoxifen-resistant cell line ERα S118 phosphorylation was found to be elevated, and ligandindependent activation of ERα through phosphorylation of S118 may contribute to tamoxifen resistance. 41, 43, 44 Another study showed that phosphorylated S118 decreases ERα affinity for tamoxifen and reduces its binding to DNA in the presence of tamoxifen. 45 This may subsequently lead to reduced co-repressor recruitments by ERα in the presence of tamoxifen.
CDKs are key regulators of the cell cycle. 46 In many human cancers, CDKs are overactive or CDK-inhibiting proteins are not functional. 47, 48 Compared with other members of the CDK family, little is known about CDK3. Although CDK3 is closely related to CDK2, it is not required for cell cycle progression in normal cells. This is based on its low expression in human tissue and spontaneous mutational inactivation in the germline of laboratory mice. 49 In cancer cell lines and tumor tissues, CDK3 is overexpressed. 32, 50 The gene for CDK3 has been mapped to chromosome 17q22-qter telomeric to the BRCAl locus, which is associated with chromosome rearrangement in breast cancer. This rearrangement results in deregulation of CDK3 gene expression or the production of an abnormal transcript of CDK3 in MDA-MB-543 cells. 51 Indeed, we found that CDK3 is hardly detectable in normal breast tissue but exhibits a higher level in breast cancer tissue. This tumor selectivity distinguishes CDK3 as a cancer target from cell cycle-regulating CDKs (CDK1, CDK2, CDK4 and CDK6). CDK3-selective inhibitor SNX9 class compounds have been approved as a patent (number EP20070809083) and clinical trials studying it efficacy are underway (https://www.sbir.gov/sbir search/detail/370403). In this study, we found that miR-873 regulates ER activity and tamoxifen resistance via targeting CDK3 but not CDK2. This finding suggests a cross-talk between ER signaling and CDK3. Based on this, one potential treatment option could be a combination of tamoxifen and a CDK3 inhibitor, which would work synergistically to prevent ER-positive cell proliferation.
Palbociclib, a small molecule inhibitor of CDK4 and CDK6, has shown considerable efficacy in ER-positive breast cancer cell lines and xenograft models. Combinations of palbociclib with tamoxifen have proven to be synergistic in ER-positive cell lines. 34 Studies are needed to test the effects of SNX9 class compounds in ER-positive breast cancer and the synergistic effect of its combination with tamoxifen.
Apparently, one miRNA may regulate many genes as its targets, while one gene may be targeted by many miRNAs. Thus, miR-873 is very likely to regulate other genes simultaneously to inhibit breast tumor growth. In addition, CDK3 can also be targeted by other miRNAs than miR-873. We postulated that one signal axis such as miR-873/CDK3 has a critical role in specific cellular signaling and its function in breast cancer depends on the genetic context. Despite multiple relationships, our data provide solid evidences that the miR-873/CDK axis has an important role in breast cancer cell growth and tamoxifen resistance in breast cancer cells. Thus, we strongly believe that targeting this pathway may be a potential therapeutic approach for the treatment of ERpositive breast cancer.
MATERIALS AND METHODS
Cell culture
The human breast cancer cell lines MCF-7, ZR75-1, T47D, SKBR3, MDA-MB-231 and HEK293T were purchased from American type culture collection (ATCC, Manassas, VA, USA). Cell lines were authenticated on the basis of viability, recovery, growth and morphology. The expression status of ER was further confirmed by western blotting before they were used in the experiments. All cells were cultured in Dulbecco's modified Eagle's media medium containing 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific, Florence, KY, USA) at 37°C with 5% CO 2 in tissue culture incubators. 17β-estradiol (E2) and 4-hydroxytamoxifen (TAM) were purchased from Sigma (St Louis, MO, USA). Tamoxifen-resistant cells (MCF-7/TamR) were developed by culturing tamoxifen-sensitive MCF-7 cells in the presence of 1 μM TAM for more than 1 year. For experiments involving E2 or TAM treatments, cells were routinely cultured in phenol red-free Dulbecco's modified Eagle's media plus 10% charcoal-stripped fetal bovine serum for at least 3 days before the treatments.
Plasmids and lentiviral vector preparation
The plasmid pERE-TK-Luc, pRL-CMV and scramble shRNA expression constructs were described previously. 35 To generate lentiviral constructs, miR-873 (Gene ID: 100126316) and CDK3 (Gene ID: 1018) genes were separately generated by PCR amplification and the PCR products were then cloned into pCDH-CMV (System Biosciences, Mountain View, CA, USA). High-titer lentivirus were generated by transient transfection of HEK293T cells. Anti-miR-873 inhibitor and control oligonucleotides were purchased from Invitrogen (Carlsbad, CA, USA).
Generation of stable cell lines
Cells were infected with lentivirus containing miR-873 and monoclonal cell lines were generated using 2 μg/ml puromycin (Sigma). In order to restore CDK3 expression in miR-873-overexpressed cell line, we treated these cells with lentivirus containing CDK3 and seeded cells in a 96-well plate with 1-2 cells in each well. Two to three months later, CDK3 and miR-873 expressions were detected by real-time PCR and western blotting using CDK3 antibody (Sigma). Primers for miR-873 were purchased from Exiqon (Vedbaek, Denmark).
Transient transfections and reporter gene assays
For transfection, cells were plated in 24-well plates containing Phenol Redfree RPMI 1640 medium supplemented with 10% charcoal-stripped fetal bovine serum, and the plasmids were transfected with Lipofectamine 2000 (Invitrogen). Following transfection, the cells were treated with E2 or TAM for 24 h and then collected for the dual luciferase assay. The dual luciferase reporter assay system (Promega, Madison, WI, USA) was employed to measure the luciferase activity.
Real-time PCR
Total RNA was isolated from cells with an Rneasy Mini kit (Qiagen, Hilden, Germany) or Trizol (Invitrogen) reagent, according to the manufacturer's instructions. Total RNA from each sample was reverse transcribed with oligo(dT) 20 using SuperScript III Reverse Transcriptase (Invitrogen) followed by real-time PCR. Primers for miR-873 were purchased from Exiqon. Primer sequences for TFF1 and c-Myc were described previously. 52 Real-time PCR was performed with SYBR Green PCR Master Mix reagents using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation analysis was performed as described previously. 53 In brief, MCF-7 and MCF-7/TamR cells were treated for 45 min with vehicle (ethanol), 100 nM E2 or 1 μM TAM, and immediately fixed by adding 37% formaldehyde to the medium, to a final concentration of 1%. After washing with phosphate-buffered saline, cells were collected with lysis buffer. The nuclear lysates were sonicated to generate an average DNA size of 0.5-1 kb, and then immunoprecipitation was performed with anti-ERα, anti-N-CoR or anti-SMRT (Santa Cruz Biotechnology, Dallas, TX, USA). Real-time PCR amplification was performed with DNA extracted from the immunoprecipitates. The primers for TFF1 and c-Myc promoter were described previously. 52 MTT assay MTT (Sigma-Aldrich, Saint Louis, MO, USA) assay was performed as described previously, with minor modifications. 52 Cells were seeded and treated with vehicle, E2 or TAM as indicated. MTT was added to the medium to a final concentration of 0.5 mg/ml and then the medium was removed and 0.2 ml DMSO was added. After incubation for 30 min in room temperature, the absorbance of the converted dye was measured at 570 nm using a Synergy spectrophotometer.
Soft agar assay
For anchorage-independent growth, 5 × 10 3 cells were plated on six-well plates containing a bottom layer of 0.6% low-melting-temperature agar in Dulbecco's modified Eagle's media and a top layer of 0.3% agar in Dulbecco's modified Eagle's media. Colonies were scored and photographed after 3 weeks of growth.
Co-immunoprecipitation
Co-immunoprecipitation assay was performed as described previously. 54 In brief, cells were treated with 10 nM E2 or vehicle for 1 h. Cells were collected and lysed in 0.5 ml lysis buffer (50 mM Tris, pH 8.0, 250 mM NaCl, 0.25% NP-40, 1 mM dithiothreitol and protease inhibitor tablets from Roche (Penzberg, Germany) and immunoprecipitation was performed with anti-FLAG M2 affinity gel, anti-CDK3 (Sigma), anti-ERα (Cell Signaling Technology, Danvers, MA, USA) or anti-MYC (Santa Cruz Biotechnology). The beads were washed and resolved by SDS-polyacrylamide gel electrophoresis, followed by immunoblotting.
GST pull-down assay ERα 1-282 was inserted into the Pgex-4T1 vector and expressed as GSTfusion proteins in Escherichia coli strain BL21 and bound to glutathione-Sepharose beads purified as described by the manufacturer (Amersham Biosciences, Piscataway, NJ, USA). The expression plasmids FLAG-CDK3 were transfected into HEK293T cells and the cell lysate was incubated with about 1 μg of GST alone or GST-ERα 1-282 fusion protein bound to glutathione-Sepharose beads in 500 μl of binding buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 0.1% Nonidet P-40, 10% glycerol, 1 mM dithiothreitol and protease inhibitor tablets from Roche Applied Science (Penzberg, Germany) at 4°C or 6 h. The beads were precipitated, washed three times with binding buffer and subjected to SDS-polyacrylamide gel electrophoresis and western blotting using anti-FLAG antibody (Sigma).
Kinase assay
An in vitro kinase assay was conducted with active Cdk3 and GST-ERα (1-282) fusion protein according to a previous study. 55 Briefly, lysates of cells stably transfected with Cdk3 were subjected to immunoprecipitation with Cdk3 antibody. The immune complex was incubated with GST-ERα (1-282) fusion protein at 30°C for 30 min and then resolved by 12% SDSpolyacrylamide gel electrophoresis. ERα phosphorylation at Ser104/106 and Ser118 was analyzed by western blotting using phospho-specific antibodies. Phospho-ERα-S104/106, S118 and anti-ERα antibodies were purchased from Cell Signaling Technology.
Immunohistochemistry staining
Immunohistochemistry staining of human breast cancer tissue microarray (Superchip, Shanghai, China) was carried out essentially as previously described. 35 In brief, the slide was first deparaffinized and subjected to heat-induced antigen retrieval using citrate buffer. The tissue sections were then incubated with primary antibodies against CDK3 (Abcam, Cambridge, MA, USA) overnight at 4°C, followed by extensive washes. The slide was subsequently treated with biotinylated anti-rabbit secondary antibody and then developed using avidin-conjugated horseradish peroxidase with diaminobenzidine as the substrate. Hematoxylin was used for counterstaining and the images were visualized and captured using Axioplan Imaging 2e microscope (Carl Zeiss, Oberkochen, Germany).
Human tissue analysis
Breast tumor and adjacent noncancerous tissues were obtained from the Affiliated Hospital of Jiujiang University, with the informed consent of patients and with approval for experiments from the Affiliated Hospital of Jiujiang University. Tissue samples were used for RNA and protein extraction to examine miR-873 and CDK3 expressions.
Animal experiments MCF-7 or MCF-7/TamR cells (1 × 10 7 ) that stably expressed miR-873 or control plasmids were injected into the abdominal mammary fat pad of 6week-old female nude mice. When tumors reached the volume of~100 mm 3 , we randomly allocated the mice to groups in which they received placebo or tamoxifen pellets (Innovative Research of America, Sarasota, FL, USA). Tumor growth was monitored by caliper measurements. Excised tumors were weighed and portions were frozen in liquid nitrogen. All the experimental procedures involving animals were conducted in accordance with Institutional Animal Care guidelines and approved ethically by the Administration Committee of Experimental Animals, Institute of Disease Control and Prevention, Chinese Academy of Military Medical Sciences, Beijing, China. The protocol number is IACUC-2013035.
